Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?
Keywords:
angiotensin-converting enzyme 2, chronic spontaneous urticaria, COVID-19, omalizumab, activationAbstract
Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era.
Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 infection.
Methods: In this retrospective study, files of CSU patients using OMZ during the COVID-19 pandemic were reviewed in terms of demographic features, medical history including COVID-19 vaccination status, clinical characteristics, pretreatment laboratory parameters, duration, and dosing regimen of OMZ treatment. Patients with a history of COVID-19 infection while on OMZ therapy and patients without COVID-19 history were compared with respect to these parameters. The urticaria activations following COVID-19 infection or vaccination were also recorded.
Results: Sixty-eight patients with CSU (female:male ratio= 1.8:1; mean age= 47.2 ± 15.1 years) continued to receive OMZ treatment. The median duration of OMZ treatment was 12 months (range: 6-60). Twelve patients (17.6%) were diagnosed with COVID-19 showing no exacerbation in urticaria. The duration of OMZ treatment was significantly higher in the group with COVID-19 infection history compared to patients with no history of COVID-19 (p=0.01). Among 51 patients (75%) vaccinated against COVID-19, urticaria activation occurred in four patients without any recurrence following booster vaccinations.
Conclusions: Considering the likelihood of increased COVID-19 infection risk in the setting of long-term OMZ in CSU patients, the duration of OMZ therapy might be kept at a minimum, or a temporary interruption of the treatment period might be preferred, particularly in high-risk patients regarding COVID-19.
References
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. DOI:10.1111/all.13397. PMID: 29336054.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. DOI: 10.1111/all.15090. PMID: 34536239.
Muntean IA, Pintea I, Bocsan IC, Dobrican CT, Deleanu D. COVID-19 Disease Leading to Chronic Spontaneous Urticaria Exacerbation: A Romanian Retrospective Study. Healthcare (Basel). 2021;9(9):1144. DOI: 10.3390/healthcare9091144. PMID: 34574918. PMCID: PMC8470475.
Allegra A, Asero R, Giovannetti A, Isola S, Gangemi S. Urticaria and coronavirus infection: a lesson from SARS-CoV-2 pandemic. Eur Ann Allergy Clin Immunol. 2021;53(2):51-54. DOI: 10.23822/EurAnnACI.1764-1489.173. PMID: 33034169.
Algaadi SA. Urticaria and COVID-19: A review. Dermatol Ther. 2020;33(6):e14290. DOI: 10.1111/dth.14290. PMID: 32902087.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407. DOI: 10.1016/j.healun.2020.03.012. PMID: 32362390. PMCID: PMC7118652.
Nicastri E, Petrosillo N, Ascoli Bartoli T, et al. National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. DOI: 10.4081/idr.2020.8543. PMID: 32218915. PMCID: PMC7097833.
Esquivel A, Busse WW, Calatroni A, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017;196(8):985-992. DOI: 10.1164/rccm.201701-0120OC. PMID: 28608756. PMCID: PMC5649984.
Gill MA, Bajwa G, George TA, et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol. 2010;184(11):5999-6006. DOI:10.4049/jimmunol.0901194. PMID: 20410486. PMCID: PMC4820019.
Durrani SR, Montville DJ, Pratt AS, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012;130(2):489-495. DOI:10.1016/j.jaci.2012.05.023. PMID: 22766097. PMCID: PMC3437329.
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-6.e1. DOI: 10.1016/j.jaci.2012.07.047. PMID: 23021878.
Farmani AR, Mahdavinezhad F, Moslemi R, et al. Anti-IgE monoclonal antibodies as potential treatment in COVID-19. Immunopharmacol Immunotoxicol. 2021;43(3):259-264. DOI: 10.1080/08923973.2021.1925906. PMID: 34018464. PMCID: PMC8146297.
Passante M, Napolitano M, Dastoli S, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther. 2021;34(6):e15111. DOI: 10.1111/dth.15111. PMID: 34427028. PMCID: PMC8646731.
Lam HY, Tergaonkar V, Kumar AP, Ahn KS. Mast cells: Therapeutic targets for COVID-19 and beyond. IUBMB Life. 2021;73(11):1278-1292. DOI: 10.1002/iub.2552. PMID: 34467628. PMCID: PMC8652840.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cell. 2020;181(2):281-292.e6.DOI:10.1016/j.cell.2020.02.058. PMID: 32155444. PMCID: PMC7102599.
Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration. 2010;80(6):534-542. DOI: 10.1159/000317137. PMID: 20588001.
Zhang H, Li Y, Zeng Y, Wu R, Ou J. Endothelin-1 downregulates angiotensin-converting enzyme-2 expression in human bronchial epithelial cells. Pharmacology. 2013;91(5-6):297-304. DOI: 10.1159/000350395. PMID: 23751363.
Chen J, Jiang Q, Xia X, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020;19(7):e13168. DOI:10.1111/acel.13168. PMID: 32558150. PMCID: PMC7323071.
Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1-7. DOI: 10.1016/j.jaci.2020.04.021. PMID: 32344056. PMCID: PMC7194727.
Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH. Eosinopenia and COVID-19. J Am Osteopath Assoc. 2020 Jul 16. DOI: 10.7556/jaoa.2020.091. Epub ahead of print. PMID: 32672799.
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. DOI:10.1111/all.14238. PMID: 32077115.
Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. DOI:10.1016/j.jaci.2020.04.006. PMCID: PMC7152876.
Polly S, Fernandez AP. Common skin signs of COVID-19 in adults: An update. Cleve Clin J Med. 2022;89(3):161-167. DOI: 10.3949/ccjm.89a.21126. PMID: 35232829.
Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin. 2021;39(4):653-673. DOI: 10.1016/j.det.2021.05.016. PMID: 34556254. PMCID: PMC8165093.
Ayhan E, Öztürk M, An İ, Bekçibaşi M. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. Int J Dermatol. 2021;60(2):253- 254. DOI: 10.1111/ijd.15379. PMID: 33332576.
Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416-1424. DOI: 10.1080/13685538.2020.1774748. PMID: 32508193.
Published
Issue
Section
License
Copyright (c) 2023 ÖZGE KAYA, Zeynep Keskinkaya, Selda Işık MERMUTLU, Sevilay Oğuz KILIÇ, Sevgi ÖZTÜRK
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
